Molecular Vision Limited (Molecular Vision) has appointed Peter Woodford as non-executive chairman of the company, effective February 15, 2009. Woodford has over 35 years' experience in the diagnostics industry. Most recently he spent 15 years with Roche Diagnostics/Boehringer Mannheim, where he was responsible for all global strategic and commercial activities at Roche Diabetes Care.
Molecular Vision’s previous chairman, chris wright, will continue to serve on the board as a non-executive director.
The appointment serves to strengthen the board as the company prepares to commercialise its novel detection technology, focussing on low cost POC diagnostic tests in a minaturised, easy-to-use, disposable format.
Commenting on the appointment Ian Campbell, chief executive officer, Molecular Vision, said: “We are delighted to attract someone of Peter’s calibre. His extensive experience and expertise of the global diagnostics industry perfectly complement the range of skills offered by the existing members of the Board.”
Woodford commented: “I am excited by the clear potential of Molecular Vision’s technology platform, and look forward to working with the team as we move towards commercialisation.”